Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
Su Mason a Northern and Yorkshire Clinical Trials and
Research Unit, University of Leeds, Leeds LS2 9NG, b Medical Care Research Unit, University of
Sheffield, Sheffield S1 4DA, c Department of Public Health and Epidemiology, University of
Birmingham, Birmingham B15 2TT Correspondence to:
Professor Lilford (r.j.lilford@bham.ac.uk)
| The first 150 words of the full text of this article appear below. |
The performance of individual clinicians is being monitored as never before. Su Mason and colleagues discuss the implications of this for clinical trials and recommend what should happen if during a trial the performance of one clinician or one centre is identified as being particularly poor. Tom Treasure, a surgeon, wants the monitoring to be done fairly and to take account of the complexities of clinical practice; and Heather Goodare, a patient, wants to be told when things go wrong.
The Department of Health in England has issued
guidelines for research governance stating that healthcare
organisations remain responsible for the quality of all aspects of
patients' care whether or not some aspects of the care are part of a
research study.1 We discuss how this obligation can be met
in multicentre trials, given that data on the performance of clinicians
are held by the trial management team, not by the